FDA Approves DIVALPROEX SODIUM — First Nation Group, LLC

First Nation Group, LLC secured FDA approval for its generic version of DIVALPROEX SODIUM on August 12, 2025, targeting the oral formulation previously marketed under another brand. This approval is projected to intensify generic competition in the mood stabilizer market, potentially pressuring competitor pricing and broadening access for patients requiring DIVALPROEX SODIUM.